METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY

• US 20160208216A1
• Filed: 01/15/2016
• Published: 07/21/2016
• Est. Priority Date: 12/08/2009
• Status: Abandoned Application

• Current Assignee: Baylor College of Medicine (Baylor College), Wilson Wolf Manufacturing Corporation
• Original Assignee: Baylor College of Medicine (Baylor College)
• Inventors: Vera, Juan F., Rooney, Cliona M., Leen, Ann M., Wilson, John R.
• Application Number:
  US14/996,447
• Publication Number:
  US 20160208216A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 2039/55527 Interleukins
• CPC Class Codes: A61K 2039/55533 IL-2
• CPC Class Codes: A61K 2239/26 Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
• CPC Class Codes: A61K 2239/48 Blood cells, e.g. leukemia or lymphoma
• CPC Class Codes: A61K 2239/58 Prostate
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4621 immunosuppressive or immunotolerising
• CPC Class Codes: A61K 39/4631 Chimeric Antigen Receptors [CAR]
• CPC Class Codes: A61K 39/46433 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61K 39/46434 Antigens related to induction of tolerance to non-self
• CPC Class Codes: A61K 39/464493 Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
• CPC Class Codes: A61K 39/464838 Viral antigens
• CPC Class Codes: A61K 48/0033 the non-active part being non-polymeric
• CPC Class Codes: A61K 51/08 Peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins
• CPC Class Codes: A61K 9/5068 Cell membranes or bacterial membranes enclosing drugs with additional exogenous lipids A61K9/127; virus envelopes A61K9/5184
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 2319/03 containing a transmembrane segment
• CPC Class Codes: C12M 23/24 Gas permeable parts
• CPC Class Codes: C12N 15/115 : Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/16 : Aptamers
• CPC Class Codes: C12N 2320/32 : Special delivery means, e.g. tissue-specific
• CPC Class Codes: C12N 2502/11 : blood or immune system cells
• CPC Class Codes: C12N 2502/1107 : B cells
• CPC Class Codes: C12N 5/0636 : T lymphocytes
• CPC Class Codes: C12N 5/0638 : Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Abstract

Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.

Claims

1. A T-Vehicle comprising:

a human T cell that has been obtained from a healthy donor and

has a native T cell receptor and

has been modified to include a therapeutic attribute and

the only antigen the modified T cell is able to recognize is a non-human antigen.

2. The T-Vehicle of claim 1 where the therapeutic attribute includes a chemotherapeutic agent.

3. The T-Vehicle of claim 1 where the therapeutic attribute includes an antimicrobial agent.

4. The T-Vehicle of claim 1 where the therapeutic attribute includes a radio isotope.

5. The T-Vehicle of claim 1 where the therapeutic attribute includes DNA.

6. The T-Vehicle of claim 1 where the therapeutic attribute includes RNA.

7. The T-Vehicle of claim 1 where the therapeutic attribute includes a recombinant protein.

8. The T-Vehicle of claim 1 where the therapeutic attribute includes a peptide.

9. The T-Vehicle of claim 1 where the therapeutic attribute includes an aptamer.

10. The T-Vehicle of claim 1 where in the T-Vehicle is frozen.

11. The T-Vehicle of claim 1 where the T-Vehicle is stored in an allogeneic cell bank.

12. A T-Vehicle comprising:

a human T cell with a native T cell receptor that only recognizes a non-human antigen wherein the T cell has been modified to make the T cell a transport vehicle that can deliver a therapeutic attribute comprising a chemotherapeutic agent, antimicrobial agent, radio isotope, DNA, RNA, recombinant protein, peptide, or aptamer.

13. The T-Vehicle of claim 12 where the human T cell is obtained from a healthy donor.

14. The T-Vehicle of claim 12 where the T-Vehicle is frozen.

15. A T-Vehicle comprising:

a T cell that includes a native T cell receptor that only recognizes antigens that are not present on normal human cells and

has been modified to include a therapeutic attribute and

is frozen and stored in an allogeneic cell bank.